JAC Advance Access originally published online on December 14, 2005
Journal of Antimicrobial Chemotherapy 2006 57(2):339-343; doi:10.1093/jac/dki445
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Effect of 1-(1-naphthylmethyl)-piperazine, a novel putative efflux pump inhibitor, on antimicrobial drug susceptibility in clinical isolates of Escherichia coli
1 Center for Infectious Diseases and Travel Medicine, Department of Medicine, University Hospital, Freiburg, Germany; 2 Section of Hospital Hygiene, Department of Medical Microbiology and Hygiene, University of Ulm, Ulm, Germany
Received 30 August 2005; returned 28 October 2005; revised 9 November 2005; accepted 11 November 2005
* Correspondence address. Medizinische Universitätsklinik, Hugstetter Strasse 55, D-79106 Freiburg, Germany. Tel: +49-761-270-1819; Fax: +49-761-270-1820; E-mail: kern{at}if-freiburg.de
Objectives: 1-(1-Naphthylmethyl)-piperazine (NMP) has been shown to reverse multidrug resistance (MDR) in Escherichia coli overexpressing resistance–nodulation–cell division type efflux pumps, but there is no data on its activity in clinical isolates of E. coli.
Methods: The antimicrobial susceptibility of 60 clinical isolates of E. coli to a variety of antimicrobial agents was determined in the absence and presence of NMP and, for comparison, of Phe-Arg-ß-naphthylamide (PAßN), another putative efflux pump inhibitor (EPI). The intracellular accumulation of ethidium bromide was measured to confirm efflux pump inhibition as the likely mechanism of action of NMP.
Results: Based on a 4-fold or greater reduction of the MIC after the addition of NMP in >50% of the isolates, significant effects of NMP at a concentration of 100 mg/L were seen for levofloxacin, linezolid and ethidium bromide. The ethidium bromide MIC changes after NMP addition correlated with differences in the ethidium bromide intracellular accumulation as measured by fluorometry in whole cell accumulation experiments. The activity of PAßN was different from that of NMP, in particular regarding macrolide resistance reversal, suggesting different modes of action of the two putative EPIs.
Conclusions: NMP is moderately active in reversing MDR in clinical isolates of E. coli and can partially restore fluoroquinolone susceptibility through inhibition of efflux pumps.
Keywords: multidrug resistance , fluoroquinolones , nosocomial pathogens
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. Chusri, I. Villanueva, S. P. Voravuthikunchai, and J. Davies Enhancing antibiotic activity: a strategy to control Acinetobacter infections J. Antimicrob. Chemother., December 1, 2009; 64(6): 1203 - 1211. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Sierra, M. Ortega, C. Tarrago, C. Albet, J. Vila, J. Terencio, and A. Guglietta Decreased linezolid uptake in an in vitro-selected linezolid-resistant Staphylococcus epidermidis mutant J. Antimicrob. Chemother., November 1, 2009; 64(5): 990 - 992. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. R. Bina, J. A. Philippart, and J. E. Bina Effect of the efflux inhibitors 1-(1-naphthylmethyl)-piperazine and phenyl-arginine-{beta}-naphthylamide on antimicrobial susceptibility and virulence factor production in Vibrio cholerae J. Antimicrob. Chemother., January 1, 2009; 63(1): 103 - 108. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Kvist, V. Hancock, and P. Klemm Inactivation of Efflux Pumps Abolishes Bacterial Biofilm Formation Appl. Envir. Microbiol., December 1, 2008; 74(23): 7376 - 7382. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Kumar, I. A. Khan, S. Koul, J. L. Koul, S. C. Taneja, I. Ali, F. Ali, S. Sharma, Z. M. Mirza, M. Kumar, et al. Novel structural analogues of piperine as inhibitors of the NorA efflux pump of Staphylococcus aureus J. Antimicrob. Chemother., June 1, 2008; 61(6): 1270 - 1276. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Schumacher, R. Trittler, J. A. Bohnert, K. Kummerer, J.-M. Pages, and W. V. Kern Intracellular accumulation of linezolid in Escherichia coli, Citrobacter freundii and Enterobacter aerogenes: role of enhanced efflux pump activity and inactivation J. Antimicrob. Chemother., June 1, 2007; 59(6): 1261 - 1264. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Bohnert, S. Schuster, E. Fahnrich, R. Trittler, and W. V. Kern Altered spectrum of multidrug resistance associated with a single point mutation in the Escherichia coli RND-type MDR efflux pump YhiV (MdtF) J. Antimicrob. Chemother., June 1, 2007; 59(6): 1216 - 1222. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Mahamoud, J. Chevalier, S. Alibert-Franco, W. V. Kern, and J.-M. Pages Antibiotic efflux pumps in Gram-negative bacteria: the inhibitor response strategy J. Antimicrob. Chemother., June 1, 2007; 59(6): 1223 - 1229. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D.-H. Kwon and C.-D. Lu Polyamine Effects on Antibiotic Susceptibility in Bacteria Antimicrob. Agents Chemother., June 1, 2007; 51(6): 2070 - 2077. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Castanheira, A. S. Pereira, A. G. Nicoletti, A. C. C. Pignatari, A. L. Barth, and A. C. Gales First Report of Plasmid-Mediated qnrA1 in a Ciprofloxacin-Resistant Escherichia coli Strain in Latin America Antimicrob. Agents Chemother., April 1, 2007; 51(4): 1527 - 1529. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Mesaros, Y. Glupczynski, L. Avrain, N. E. Caceres, P. M. Tulkens, and F. Van Bambeke A combined phenotypic and genotypic method for the detection of Mex efflux pumps in Pseudomonas aeruginosa J. Antimicrob. Chemother., March 1, 2007; 59(3): 378 - 386. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Pannek, P. G. Higgins, P. Steinke, D. Jonas, M. Akova, J. A. Bohnert, H. Seifert, and W. V. Kern Multidrug efflux inhibition in Acinetobacter baumannii: comparison between 1-(1-naphthylmethyl)-piperazine and phenyl-arginine-{beta}-naphthylamide J. Antimicrob. Chemother., May 1, 2006; 57(5): 970 - 974. [Abstract] [Full Text] [PDF]
|
|